RU2344121C2 - Способы лечения заболеваний у млекопитающих - Google Patents

Способы лечения заболеваний у млекопитающих Download PDF

Info

Publication number
RU2344121C2
RU2344121C2 RU2006107650/04A RU2006107650A RU2344121C2 RU 2344121 C2 RU2344121 C2 RU 2344121C2 RU 2006107650/04 A RU2006107650/04 A RU 2006107650/04A RU 2006107650 A RU2006107650 A RU 2006107650A RU 2344121 C2 RU2344121 C2 RU 2344121C2
Authority
RU
Russia
Prior art keywords
methyl
acid
amino
aminomethyl
dimethyl
Prior art date
Application number
RU2006107650/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2006107650A (ru
Inventor
Кэндас Роскоф БРАМСОН (US)
Кэндас Роскоф БРАМСОН
Джордж Майкл ХЭЙГ (US)
Джордж Майкл ХЭЙГ
Денис Дж. ШРАЙЕР (US)
Денис Дж. ШРАЙЕР
Фонг ВАНГ (US)
Фонг ВАНГ
Original Assignee
УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си filed Critical УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си
Publication of RU2006107650A publication Critical patent/RU2006107650A/ru
Application granted granted Critical
Publication of RU2344121C2 publication Critical patent/RU2344121C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
RU2006107650/04A 2003-09-25 2004-09-13 Способы лечения заболеваний у млекопитающих RU2344121C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50600303P 2003-09-25 2003-09-25
US60/506,003 2003-09-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2008137379/04A Division RU2008137379A (ru) 2003-09-25 2008-09-19 Терапевтические бета-аминокислоты

Publications (2)

Publication Number Publication Date
RU2006107650A RU2006107650A (ru) 2007-10-27
RU2344121C2 true RU2344121C2 (ru) 2009-01-20

Family

ID=34393101

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2006107650/04A RU2344121C2 (ru) 2003-09-25 2004-09-13 Способы лечения заболеваний у млекопитающих
RU2008137379/04A RU2008137379A (ru) 2003-09-25 2008-09-19 Терапевтические бета-аминокислоты

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2008137379/04A RU2008137379A (ru) 2003-09-25 2008-09-19 Терапевтические бета-аминокислоты

Country Status (15)

Country Link
US (2) US7112610B2 (cg-RX-API-DMAC7.html)
EP (1) EP1670452A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007506726A (cg-RX-API-DMAC7.html)
KR (1) KR100774625B1 (cg-RX-API-DMAC7.html)
CN (1) CN1856301A (cg-RX-API-DMAC7.html)
AU (1) AU2004275572A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414798A (cg-RX-API-DMAC7.html)
CA (1) CA2539976A1 (cg-RX-API-DMAC7.html)
IL (1) IL173862A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06003381A (cg-RX-API-DMAC7.html)
NO (1) NO20061801L (cg-RX-API-DMAC7.html)
RU (2) RU2344121C2 (cg-RX-API-DMAC7.html)
TW (1) TW200511989A (cg-RX-API-DMAC7.html)
WO (1) WO2005030184A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200602450B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX355728B (es) 2011-05-17 2018-04-27 Univ California Inhibidores de cinasas.
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
ES2604191T3 (es) 2011-05-17 2017-03-03 Principia Biopharma Inc. Inhibidores de tirosina quinasas
BR112015003859B1 (pt) 2012-09-10 2023-04-11 Principia Biopharma Inc. Composto e/ou sal farmaceuticamente aceitável do mesmo, respectivo uso e composição farmacêutica
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CA2939186C (en) 2014-02-21 2023-03-07 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
ES2843323T3 (es) 2014-12-18 2021-07-16 Principia Biopharma Inc Tratamiento de pénfigo
WO2016210165A1 (en) 2015-06-24 2016-12-29 Principia Biopharma Inc. Tyrosine kinase inhibitors
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
US20210106584A1 (en) 2019-10-14 2021-04-15 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
TW202140484A (zh) 2020-01-22 2021-11-01 美商普林斯匹亞生物製藥公司 2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)-1H-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧環丁烷-3-基)哌𠯤-1-基]戊-2-烯腈之晶形

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2147574C1 (ru) * 1991-08-23 2000-04-20 Эн-Пи-Эс Фармасьютикалз, Инк. Арилалкиламины, композиции, способы лечения и диагностики, способы идентификации соединения
WO2000059864A1 (fr) * 1999-04-06 2000-10-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibiteurs de lta4 hydrolase
WO2002073208A2 (en) * 2001-03-13 2002-09-19 Queen's University At Kingston Anti-epileptogenic agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2147574C1 (ru) * 1991-08-23 2000-04-20 Эн-Пи-Эс Фармасьютикалз, Инк. Арилалкиламины, композиции, способы лечения и диагностики, способы идентификации соединения
WO2000059864A1 (fr) * 1999-04-06 2000-10-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibiteurs de lta4 hydrolase
WO2002073208A2 (en) * 2001-03-13 2002-09-19 Queen's University At Kingston Anti-epileptogenic agents

Also Published As

Publication number Publication date
AU2004275572A1 (en) 2005-04-07
TW200511989A (en) 2005-04-01
KR100774625B1 (ko) 2007-11-08
RU2008137379A (ru) 2010-03-27
ZA200602450B (en) 2007-09-26
IL173862A0 (en) 2006-07-05
US20050124669A1 (en) 2005-06-09
CA2539976A1 (en) 2005-04-07
MXPA06003381A (es) 2006-06-08
JP2007506726A (ja) 2007-03-22
BRPI0414798A (pt) 2006-11-21
US7112610B2 (en) 2006-09-26
KR20060056391A (ko) 2006-05-24
US20060247282A1 (en) 2006-11-02
WO2005030184A2 (en) 2005-04-07
WO2005030184A3 (en) 2005-06-02
RU2006107650A (ru) 2007-10-27
EP1670452A2 (en) 2006-06-21
CN1856301A (zh) 2006-11-01
NO20061801L (no) 2006-06-02

Similar Documents

Publication Publication Date Title
US7517909B2 (en) Amino acids with affinity for the α2δ-protein
RU2344121C2 (ru) Способы лечения заболеваний у млекопитающих
JP2006328078A (ja) カルシウムチャンネルα2δサブユニットに親和性を有するプロリン誘導体
AU2005203759B2 (en) Amino acids with affinity for the alpha-2-delta-protein

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090914